Stress Studies of Tenofovir Disoproxil Fumarate by HPTLC in Bulk Drug and Pharmaceutical Formulation by Shweta Havele, Sunil R. Dhaneshwar

“…A stability-indicating high-performance thin-layer chromatographic (HPTLC) method for determination of tenofovir disoproxil fumarate in bulk drug and in tablet has been developed and validated. …”
Get full text

Development and Validation of UV-Visible Spectrophotometric Baseline Manipulation Method for Simultaneous Quantitation of Tenofovir Disoproxil Fumarate and Emtricitabine in Pharmaceutical Dosage Form by Vishnu P. Choudhari, Sanket R. Parekar, Subhash G. Chate, Pradeep D. Bharande, Rajiv R. Singh, Bhanudas S. Kuchekar

“…A simple, economical, precise, and accurate new UV-visible spectrophotometric baseline manipulation method for simultaneous determination of tenofovir disoproxil fumarate (TE) and emtricitabine (EM) in combined tablet dosage form has been developed. …”
Get full text

Real-World Analysis of Weight Gain and Body Mass Index Increase Among Patients with HIV-1 Using Antiretroviral Regimen Containing Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate, or Neither in the United States by Bruno Emond, Carmine Rossi, Rachel Rogers, Patrick Lefebvre, Marie-Hélène Lafeuille, Prina Donga

“…Adult patients with HIV-1 initiating ART (index date) containing TAF 25 mg, TAF 10 mg, tenofovir disoproxil fumarate (TDF), or neither TAF nor TDF on or after July 17, 2018, were included. …”
Get full text

Effect of potent nucleos(t)ide analog on alpha fetoprotein changes and occurrence of hepatocellular carcinoma in patients with chronic hepatitis B by Qianqian Ma, Junzhao Ye, Ling Luo, Yanhong Sun, Wei Wang, Shiting Feng, Bing Liao, Bihui Zhong

Subjects: Get full text

Lower incidence of hepatocellular carcinoma with tenofovir alafenamide in chronic hepatitis B: Evidence from a large-scale cohort by Hye-Jin Yoo, Jae-Young Kim, Jeong-Ju Yoo, Hye Won Lee, Sang Gyune Kim, Young Seok Kim

“…This study evaluated and compared the effects of TAF, tenofovir disoproxil fumarate (TDF), and entecavir (ETV) on HCC incidence using nationwide claim data. …”
Get full text

Chronic kidney disease among people living with HIV on TDF based regimen: A systematic review and meta-analysis. by Taklo Simeneh Yazie, Wondimeneh Shibabaw Shiferaw, Asaye Alamneh Gebeyehu, Assefa Agegnehu Teshome, Zenaw Debasu Addisu, Abebe Muche Belete

“…<h4>Introduction</h4>Chronic kidney disease is a major public health concern among people living with human immunodeficiency virus (PLWHIV) who are taking tenofovir disoproxil fumarate-based regimen. Despite the available evidence showing a high prevalence of CKD in this population, comprehensive pooled estimate of CKD among PLWHIV receiving TDF based regimen across the globe is lacking. …”
Get full text

Efficacy and safety of tenofovir and entecavir in patients with chronic hepatitis B-related cirrhosis: a systematic review and meta-analysis by Lu Cao, Li Li, Lixing Yang, Nan Zhou, Yu Zhang

“…Compared with the entecavir group, patients in the tenofovir group, including tenofovir disoproxil fumarate and tenofovir alafenamide fumarate showed a significant increase in estimated glomerular filtration rate after 48 weeks of treatment.ConclusionCompared to entecavir, tenofovir significantly reduced the cumulative incidence of hepatocellular carcinoma and cumulative mortality in chronic hepatitis B-related cirrhosis in East Asian population. …”
Get full text

Severe Symptomatic Hypocalcemia from HIV Related Hypoparathyroidism by Sartaj Sandhu, Akshata Desai, Manav Batra, Robin Girdhar, Kaushik Chatterjee, E. Helen Kemp, Antoine Makdissi, Ajay Chaudhuri

“…Pertinent medications included calcium carbonate, vitamin D3, calcitriol, efavirenz, emtricitabine, tenofovir disoproxil, hydrochlorothiazide, and inhaled budesonide/formoterol. …”
Get full text

Incidence of Hyperlipidemia among Adults Initiating Antiretroviral Therapy in the HIV Outpatient Study (HOPS), USA, 2007–2021 by Jun Li, Selom Agbobli-Nuwoaty, Frank J. Palella, Richard M. Novak, Ellen Tedaldi, Cynthia Mayer, Jonathan D. Mahnken, Qingjiang Hou, Kimberly Carlson, Angela M. Thompson-Paul, Marcus D. Durham, Kate Buchacz

“…Other factors independently associated with hyperlipidemia included older age, non-Hispanic White race/ethnicity, and ART without tenofovir disoproxil fumarate. PWH using RAL-based regimens had lower rates of incident hyperlipidemia than PWH receiving non-INSTI-PI-based ART but had similar rates as those receiving DTG-based ART, supporting federal recommendations for using DTG-based regimens as the initial therapy for ART-naïve PWH.…”
Get full text

Effect of Food on the Steady-State Pharmacokinetics of Tenofovir and Emtricitabine plus Efavirenz in Ugandan Adults by Mohammed Lamorde, Pauline Byakika-Kibwika, William S. Tamale, Francis Kiweewa, Mairin Ryan, Alieu Amara, John Tjia, David Back, Saye Khoo, Marta Boffito, Cissy Kityo, Concepta Merry

“…We investigated the effect of food on the steady-state pharmacokinetics of a proprietary fixed-dose combination (FDC) tablet containing tenofovir disoproxil fumarate (TDF)/emtricitabine/efavirenz. …”
Get full text

Kidney disease among adults on tenofovir-based second-line antiretroviral therapy in Dar es Salaam, Tanzania by Sabina F. Mugusi, Grace A. Shayo, Philip G. Sasi, Lulu S. Fundikira, Eric A. Aris, Christopher R. Sudfeld, Ferdinand M. Mugusi

“…Background: Kidney disease is a growing non-AIDS-related comorbidity among people living with HIV (PLWH). Tenofovir disoproxil fumarate (TDF) can result in proximal tubulopathy and acute tubular injury, whereas atazanavir/ritonavir (ATV/r) can cause interstitial nephritis and renal stones, both of which can lead to chronic kidney disease. …”
Get full text

Efficacy of Tenofovir-Based Combination Therapy versus Tenofovir Monotherapy in Chronic Hepatitis B Patients Presenting with Suboptimal Responses to Pretreatment: A Meta-Analysis by Ling Chen, Xiwei Wang, Qiongfang Zhang, Jiaojiao Gong, Shasha Shen, Wenwei Yin, Huaidong Hu

“…It remains unclear whether tenofovir disoproxil fumarate- (TDF-) based combination therapy produces better outcomes than TDF monotherapy in chronic hepatitis B (CHB) patients. …”
Get full text

HIV Drug Resistance Profile in Clients Experiencing Treatment Failure After the Transition to a Dolutegravir-Based First-Line Antiretroviral Treatment Regimen in Mozambique by Nalia Ismael, Cidia Hussein, Cacildo Magul, Humberto Inguane, Aleny Couto, Amancio Nhangave, Ana Muteerwa, Mahoudo Bonou, Artur Ramos, Peter Wesley Young, Sonia Chilundo, Rhoderick Machekano, Lauren Greenberg, Juliana da Silva, Nilesh Bhatt

“…Real-world data on HIV drug resistance (HIVDR) after transitioning to tenofovir disoproxil fumarate/lamivudine/dolutegravir (TLD) are limited. …”
Get full text

Evaluation of long‐acting cabotegravir safety and pharmacokinetics in pregnant women in eastern and southern Africa: a secondary analysis of HPTN 084 by Sinead Delany‐Moretlwe, Brett Hanscom, Xu Guo, Clemensia Nkabiito, Patricia Mandima, Patricia Ntege Nahirya, Juliet Mpendo, Muchaneta Bhondai‐Mhuri, Nyaradzo Mgodi, Rebecca Berhanu, Jennifer Farrior, Estelle Piwowar‐Manning, Susan L. Ford, Craig W. Hendrix, Alex R. Rinehart, James F. Rooney, Adeola Adeyeye, Raphael J. Landovitz, Myron S. Cohen, Mina C. Hosseinipour, Mark A. Marzinke, the HPTN 084 Study Team

“…Methods Participants were randomized 1:1 to either active cabotegravir (CAB) plus tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) placebo or active TDF/FTC plus CAB placebo. …”
Get full text